Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia

• Published in: Journal of cellular biochemistry Vol. 116; no. 8; pp. 1500 - 1512
• Main Authors: Studzinski, George P., Harrison, Jonathan S., Wang, Xuening, Sarkar, Surojit, Kalia, Vandana, Danilenko, Michael
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.08.2015; Wiley Subscription Services, Inc
• Subjects: Animals; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Calciferol; CALCITRIOL; Cell differentiation; Cell Differentiation - drug effects; Cell proliferation; Clinical trials; Clinical Trials as Topic; Differentiation (biology); Disease control; Extreme values; HEMATOPOIESIS; Hematopoiesis - drug effects; Hematopoietic stem cells; Humans; Immune response; LEUKEMIA; Leukemia - drug therapy; Leukemia - pathology; Lymphopoiesis; Malignancy; Myelopoiesis; Population studies; VITAMIN D; Vitamin D - administration & dosage; Vitamin D - analogs & derivatives; Vitamin D - pharmacology; Vitamins - administration & dosage; Vitamins - pharmacology; LEUKEMIA; HEMATOPOIESIS; VITAMIN D; CALCITRIOL
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.25104

It is now well known that in the mammalian body vitamin D is converted by successive hydroxylations to 1,25‐dihydroxyvitamin D (1,25D), a steroid‐like hormone with pleiotropic properties. These include important contributions to the control of cell proliferation, survival and differentiation, as well as the regulation of immune responses in disease. Here, we present recent advances in current understanding of the role of 1,25D in myelopoiesis and lymphopoiesis, and the potential of 1,25D and analogs (vitamin D derivatives; VDDs) for the control of hematopoietic malignancies. The reasons for the unimpressive results of most clinical studies of the therapeutic effects of VDDs in leukemia and related diseases may include the lack of a precise rationale for the conduct of these studies. Further, clinical trials to date have generally used extremely heterogeneous patient populations and, in many cases, small numbers of patients, generally without controls. Although low calcemic VDDs have been used and combined with agents that can increase the leukemia cell killing or differentiation effects in acute leukemias, the sequencing of agents used for combination therapy should to be more clearly delineated. Most importantly, it is recommended that in future clinical trials the rationale for the basis of the enhancing action of drug combinations should be clearly articulated and the effects on anticancer immunity should also be evaluated. J. Cell. Biochem. 116: 1500–1512, 2015. © 2015 Wiley Periodicals, Inc.